Mainz Biomed B.V. (MYNZ) AI Stock Analysis

• Market Cap: $7.74M
• Dividend Yield: N/A
• Average Volume (3M): 201.58K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.16
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 19
• Sector: Healthcare
• Sector Strength: 43
• Industry: Medical - Diagnostics & Research
• EPS (TTM): N/A
• Shares Outstanding: 4,577,853
• 10 Day Avg. Volume: 242,220
• 30 Day Avg. Volume: 201,582
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $7.75
• Price Target Upside: 350.58% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 41 Neutral
• Price Target: $1.50 ▼(-12.79% Downside)

Mainz Biomed B.V.'s overall stock score is primarily impacted by financial performance challenges, including negative profitability and high leverage. Technical analysis also indicates bearish momentum, with the stock trading below key moving averages. Valuation issues due to unavailable metrics further detract from the score. Improvement in financial stability and momentum is necessary for a better outlook.

Positive Factors

Market Opportunity

Mainz Biomed is poised to capture market share in the $4B colorectal cancer screening market, leveraging commercial success stories like Cologuard.

Strategic Partnerships

An agreement with Quest Diagnostics for the ReconAAsense study opens commercialization opportunities for Mainz Biomed.

Technological Advancements

The Next Generation Test from Mainz Biomed enhances detection rates for advanced adenomas using mRNA biomarkers, surpassing industry standards.

Negative Factors

Clinical Validation

The success of Mainz Biomed's detection rates depends on maintaining high sensitivity and specificity when integrating biomarkers into a commercial product.

Competition

Existing tests like Cologuard have already secured significant market presence with over $2B in annual sales, posing a challenge for Mainz Biomed.

Research and Development

Ongoing feasibility studies and the enrollment of participants in clinical trials indicate that Mainz Biomed's products are still in development phases.

Mainz Biomed B.V. Business Overview & Revenue Model

Company Description

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.

How the Company Makes Money

Mainz Biomed B.V. generates revenue primarily through the sale of its diagnostic tests, particularly its proprietary colorectal cancer screening test. The company partners with healthcare providers, laboratories, and insurance companies to distribute and administer these tests to patients. Revenue is derived from test sales, partnerships with diagnostic labs that process the tests, and potentially through licensing agreements for their technology. Additionally, collaborations with research institutions and participation in clinical studies may provide supplementary income streams or development funding.

Mainz Biomed B.V. Financial Statement Overview

Summary

Mainz Biomed B.V. faces significant financial challenges with fluctuating revenues, substantial EBIT and net losses, high leverage, and negative operating cash flow. Some improvements in equity and free cash flows are noted, but overall negative profitability and reliance on external funding pose risks.

Income Statement

Mainz Biomed B.V. has shown fluctuating revenues with recent stagnation, failing to surpass the 2020 revenue levels. Despite some improvement in gross profit margins, the company continues to incur substantial EBIT and net losses, indicating persistent profitability challenges. Net profit margin remains deeply negative, emphasizing ongoing financial hurdles.

Balance Sheet

The company exhibits high leverage with a rising debt-to-equity ratio, indicating potential financial risk. Stockholders' equity has improved recently, but overall equity is still relatively low compared to total assets, suggesting limited financial stability. Return on Equity remains negative, reflecting unprofitability.

Cash Flow

Operating cash flow has been consistently negative, although free cash flow has shown some improvement. Financing activities have been a major source of cash, highlighting reliance on external funding. The operating cash flow to net income ratio is concerning, as cash flows are not covering net losses.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	893.99K	895.48K	529.88K	577.35K	493.56K
Gross Profit	574.88K	509.66K	182.15K	177.62K	123.08K
EBITDA	-19.56M	-25.01M	-25.72M	-11.28M	-257.64K
Net Income	-21.65M	-26.30M	-26.45M	-12.07M	-886.18K
Balance Sheet
Total Assets	13.24M	15.41M	20.24M	10.04M	673.27K
Cash, Cash Equivalents and Short-Term Investments	6.24M	7.07M	17.14M	8.73M	122.57K
Total Debt	3.27M	7.42M	3.23M	2.58M	2.98M
Total Liabilities	7.19M	12.16M	6.14M	3.68M	3.41M
Stockholders Equity	6.05M	3.25M	14.10M	6.36M	-2.74M
Cash Flow
Free Cash Flow	-17.34M	-23.84M	-15.43M	-3.24M	-478.42K
Operating Cash Flow	-17.09M	-21.94M	-14.77M	-3.22M	-468.74K
Investing Cash Flow	-198.82K	-1.90M	-658.48K	1.20M	-9.69K
Financing Cash Flow	16.60M	14.23M	23.94M	10.61M	396.68K

Mainz Biomed B.V. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.72
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MYNZ, the sentiment is Neutral. The current price of 1.72 is below the 20-day moving average (MA) of 1.72, above the 50-day MA of 1.71, and below the 200-day MA of 4.37, indicating a bearish trend. The MACD of -0.07 indicates Negative momentum. The RSI at 50.42 is Neutral, neither overbought nor oversold. The STOCH value of 68.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MYNZ.

Mainz Biomed B.V. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRPO	67 Neutral	$23.82M	―	-14.76%	―	26.67%	44.02%
Sector *	60 Neutral	HK$18.14B	5.28	-4.00%	3.33%	10.16%	-17.39%
INBS	55 Neutral	$10.93M	―	-126.34%	―	3.87%	91.76%
TRIB	46 Neutral	$20.40M	―	77.20%	―	-4.02%	-6.60%
BNGO	42 Neutral	$10.80M	―	-127.82%	―	-24.04%	84.11%
MYNZ	41 Neutral	$7.74M	―	-809.29%	―	―	―
BIAF	40 Underperform	$7.80M	―	-1802.45%	―	78.40%	22.41%